Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2026)

Revolution Medicines' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 817.2% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 817.2% YoY), while the FY2025 annual figure was $1.2 million, down 62.12% from the prior year.
• Other Non-Current Liabilities was $6.9 million for Q1 2026 at Revolution Medicines, up from $1.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.2 million in Q2 2025 to a low of $219000.0 in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $2.3 million across 5 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities plunged 76.24% in 2025, then surged 817.2% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $301000.0 in 2022, then surged by 384.39% to $1.5 million in 2023, then surged by 118.72% to $3.2 million in 2024, then plunged by 62.12% to $1.2 million in 2025, then soared by 469.45% to $6.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.9 million (Q1 2026), $1.2 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.